Multi-target research partnership for drug discovery in oncology and painAssembly of novel high-diversity small molecule library Library collection distinguished by novel unique design concepts based...
Proteros receives minority investment from private equity firm Inflexion
MARTINSRIED, Germany and Munich, Germany, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH (“Proteros”) today announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics (Cambridge, UK), a leader in synthetic rescue therapies for genetic diseases. Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the company’s experienced discovery teams.
The latest announcement builds on a previous deal signed by the two companies last year, where AstraZeneca pledged up to $65 million in milestone payments, on top of research funding and royalties, to Munich-based Proteros to jointly discover and develop new small molecules for an array of oncology assets.